Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification

被引:1
作者
Prskalo, Zvjezdana Spacir [1 ]
Bulic, Petra [1 ]
Langer, Sanja [1 ]
Gace, Mihaela [1 ]
Puljiz, Mario [2 ]
Danolic, Damir [2 ]
Alvir, Ilija [2 ]
Mamic, Ivica [2 ]
Susnjar, Lucija [2 ]
Mayer, Ljiljana [1 ]
机构
[1] Univ Hosp Tumors, Sestre Milosrdnice Univ Hosp Ctr, Dept Med Biochem Oncol, Ilica 197, Zagreb 10000, Croatia
[2] Univ Hosp Tumors, Sestre Milosrdnice Univ Hosp Ctr, Dept Gynecol Oncol, Zagreb, Croatia
关键词
HE4; CA125; ROMA index; ovarian cancer; biomarker; EPIDIDYMIS PROTEIN 4; MALIGNANCY ALGORITHM; PELVIC MASS; ANTIGEN; 125; CA125; BIOMARKERS; PREDICTION; GUIDELINES; DIAGNOSIS; ACCURACY;
D O I
10.1080/01443615.2018.1476471
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This study aimed to identify and quantify the clinical significance of the HE4 and ROMA index in patients with an adnexal tumour. We recruited 159 women and the HE4 and CA125 were measured with an electrochemiluminescence immunoassay in the sera. We used the Kolmogorov-Smirnov test, Mann-Whitney's test and logistic regression to interpret the data. In the premenopausal group (n = 57), the ROC analysis (with cut-off: 86.1 pmol/L for HE4; 40.7 U/L for CA125 and 21.9% for ROMA) demonstrated the superior prognostic potential of those markers when the higher cut-offs used are compared to producers. The AUC for HE4/CA125/ROMA were 0.846/0.867/0.846, respectively. The HE4/ROMA showed 85.7% sensitivity and 94% specificity. In the postmenopausal group (n = 102), the ROC analysis cut-off values were: 99.8 pmol/L for HE4; 45.8 U/L for CA125 and 38.4% for ROMA. AUC for HE4/CA125/ROMA were 0.928/0.899/0.927, respectively. HE4 had an 86.1% sensitivity at 92.4% specificity, while ROMA showed an 88.9% sensitivity at a 90.9% specificity.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 46 条
  • [21] Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer
    Luo, Hui-Jing
    Hu, Zhi-Dong
    Cui, Ming
    Zhang, Xiao-Fang
    Tian, Wen-Yan
    Ma, Chao-Qun
    Ren, Ya-Nv
    Dong, Zuo-Liang
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2023, 49 (03) : 998 - 1006
  • [22] Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
    Vincent Dochez
    Hélène Caillon
    Edouard Vaucel
    Jérôme Dimet
    Norbert Winer
    Guillaume Ducarme
    Journal of Ovarian Research, 12
  • [23] Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women
    Fujiwara, Hiroyuki
    Suzuki, Mitsuaki
    Takeshima, Nobuhiro
    Takizawa, Ken
    Kimura, Eizo
    Nakanishi, Toru
    Yamada, Kyosuke
    Takano, Hirokuni
    Sasaki, Hiroshi
    Koyama, Koji
    Ochiai, Kazunori
    TUMOR BIOLOGY, 2015, 36 (02) : 1045 - 1053
  • [24] APPLICATION VALUE OF HE4, CA125 AND ROMA IN DIAGNOSIS OF THE OVARIAN CANCER
    Sun, Wenchao
    Wang, Jinfang
    Liu, Lubin
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1765 - 1769
  • [25] Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass
    Goff, Barbara A.
    Agnew, Kathy
    Neradilek, Moni Blazej
    Gray, Heidi J.
    Liao, John B.
    Urban, Renata R.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 291 - 295
  • [26] High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
    Kalapotharakos, Grigorios
    Asciutto, Christine
    Henic, Emir
    Casslen, Bertil
    Borgfeldt, Christer
    JOURNAL OF OVARIAN RESEARCH, 2012, 5
  • [27] Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection in Jakarta, Indonesia
    Winarto, Hariyono
    Laihad, Bismarck Joel
    Nuranna, Laila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 1949 - 1953
  • [28] A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass
    Karlsen, Mona A.
    Hogdall, Estrid V. S.
    Christensen, Ib J.
    Borgfeldt, Christer
    Kalapotharakos, Grigorios
    Zdrazilova-Dubska, Lenka
    Chovanec, Josef
    Lok, Christianne A. R.
    Stiekema, Anna
    Mutz-Dehbalaie, Irene
    Rosenthal, Adam N.
    Moore, Elizabeth K.
    Schodin, Beth A.
    Sumpaico, Walfrido W.
    Sundfeldt, Karin
    Kristjansdottir, Bjorg
    Zapardiel, Ignacio
    Hogdall, Claus K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 640 - 646
  • [29] A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
    Anton, Cristina
    Carvalho, Filomena Marino
    Oliveira, Elci Isabel
    Rosa Maciel, Gustavo Arantes
    Baracat, Edmund Chada
    Carvalho, Jesus Paula
    CLINICS, 2012, 67 (05) : 437 - 441
  • [30] Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Tests in Ovarian Cancer
    Bouzari, Zinatossadat
    Rahimi, Hadiseh
    Gholinia, Hemmat
    Yazdani, Shahla
    Hajian-Tilaki, Karimollah
    Soleimani, Mohammad Jafar
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2019, 12 (01)